HK1040919B - 有關血管生成疾病的治療組合 - Google Patents

有關血管生成疾病的治療組合

Info

Publication number
HK1040919B
HK1040919B HK02102577.5A HK02102577A HK1040919B HK 1040919 B HK1040919 B HK 1040919B HK 02102577 A HK02102577 A HK 02102577A HK 1040919 B HK1040919 B HK 1040919B
Authority
HK
Hong Kong
Prior art keywords
combinations
treatment
diseases involving
involving angiogenesis
formation
Prior art date
Application number
HK02102577.5A
Other languages
English (en)
Other versions
HK1040919A1 (en
Inventor
P‧D‧戴維斯
Original Assignee
安吉奧金藥物有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安吉奧金藥物有限公司 filed Critical 安吉奧金藥物有限公司
Publication of HK1040919A1 publication Critical patent/HK1040919A1/xx
Publication of HK1040919B publication Critical patent/HK1040919B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
HK02102577.5A 1999-02-16 2002-04-08 有關血管生成疾病的治療組合 HK1040919B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903404.3A GB9903404D0 (en) 1999-02-16 1999-02-16 Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PCT/GB2000/000511 WO2000048591A1 (en) 1999-02-16 2000-02-15 Combinations for the treatment of diseases involving angiogenesis

Publications (2)

Publication Number Publication Date
HK1040919A1 HK1040919A1 (en) 2002-06-28
HK1040919B true HK1040919B (zh) 2005-05-13

Family

ID=10847791

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102577.5A HK1040919B (zh) 1999-02-16 2002-04-08 有關血管生成疾病的治療組合

Country Status (21)

Country Link
US (2) US7087627B1 (zh)
EP (1) EP1161235B1 (zh)
JP (1) JP4708569B2 (zh)
KR (2) KR20070034642A (zh)
CN (1) CN1344159B (zh)
AT (1) ATE288264T1 (zh)
AU (1) AU775242B2 (zh)
BR (1) BR0008254A (zh)
CA (1) CA2362281C (zh)
DE (1) DE60017878T2 (zh)
DK (1) DK1161235T3 (zh)
ES (1) ES2237407T3 (zh)
GB (1) GB9903404D0 (zh)
HK (1) HK1040919B (zh)
IL (2) IL144847A0 (zh)
MX (1) MXPA01008245A (zh)
NO (1) NO20013966L (zh)
NZ (1) NZ513429A (zh)
PT (1) PT1161235E (zh)
WO (1) WO2000048591A1 (zh)
ZA (1) ZA200106688B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
US20050153939A1 (en) 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
CN1200712C (zh) * 2000-10-27 2005-05-11 阿文蒂斯药物股份有限公司 用于治疗癌症的含喜树碱和1,2－二苯乙烯衍生物的组合物
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
CN1527704B (zh) * 2001-07-13 2011-05-18 奥克斯吉尼有限公司 治疗眼病的组合物和微管蛋白结合剂用法
AU2008202468B2 (en) * 2001-07-13 2011-08-11 Oxigene, Inc. Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
SI1287854T1 (sl) * 2001-08-30 2006-08-31 Cancer Rec Tech Ltd Kombinacija DMXAA in paklitaksela ali docetakselaproti raku
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2007354255A1 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
JP5302328B2 (ja) 2007-11-21 2013-10-02 オキシジーン， インコーポレイテッド 造血性新生物を治療するための方法
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0670720A1 (en) * 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzyme inhibitors
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5424447A (en) * 1993-07-07 1995-06-13 The Medical College Of Wisconsin Research Foundation, Inc. Heme binding compounds and use thereof
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
JP2000506170A (ja) * 1996-03-05 2000-05-23 メデイノックス，インコーポレイテッド 酸化窒素スキャベンジャーを用いる複合治療方法とそのために有用な組成物
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

Also Published As

Publication number Publication date
HK1040919A1 (en) 2002-06-28
DK1161235T3 (da) 2005-05-09
EP1161235B1 (en) 2005-02-02
AU775242B2 (en) 2004-07-22
PT1161235E (pt) 2005-05-31
MXPA01008245A (es) 2002-10-23
DE60017878T2 (de) 2006-01-26
US20060198846A1 (en) 2006-09-07
CN1344159B (zh) 2011-09-28
CA2362281C (en) 2008-11-18
EP1161235A1 (en) 2001-12-12
KR20070034642A (ko) 2007-03-28
ZA200106688B (en) 2002-08-14
CN1344159A (zh) 2002-04-10
NO20013966L (no) 2001-10-15
AU2559000A (en) 2000-09-04
WO2000048591A1 (en) 2000-08-24
US7087627B1 (en) 2006-08-08
NO20013966D0 (no) 2001-08-15
IL144847A0 (en) 2002-06-30
CA2362281A1 (en) 2000-08-24
BR0008254A (pt) 2001-11-06
JP4708569B2 (ja) 2011-06-22
GB9903404D0 (en) 1999-04-07
JP2002537251A (ja) 2002-11-05
ES2237407T3 (es) 2005-08-01
KR20010102038A (ko) 2001-11-15
ATE288264T1 (de) 2005-02-15
NZ513429A (en) 2003-10-31
IL144847A (en) 2006-10-31
DE60017878D1 (de) 2005-03-10

Similar Documents

Publication Publication Date Title
IL144847A0 (en) Combinations for the treatment of diseases involving angiogenesis
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
ATE267168T1 (de) Beta-alanin-derivate als zell-adhäsions- inhibitoren
EP1017382A4 (en) BIARYLALKANOIC ACID FOR USE AS A CELL ADHESION INHIBITOR
WO1999062510A3 (en) Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
IL158559A0 (en) Acne treatment
BR9917089A (pt) Composições e métodos para distribuição mucosal
KR960703603A (ko) 프로게스테론형 제제 및 산화질소 합성효소 기질 및 산화질소 공여물질의 배합물을 사용한 자간전증 및 조산의 치료(Combination of a Progestational Agent and a Nitric Oxide Synthase substrate and/or Donor for the Treatment of Preeclampsia and Preterm Labor)
EP1113000A4 (en) BENZENE DERIVATIVES AND THEIR MEDICAL APPLICATION
AU2002213421A1 (en) Condensed pyridoindole derivatives
MXPA03010761A (es) Combinaciones farmaceuticas.
MXPA02012659A (es) Derivados de pirazindiona condensados.
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
WO2000040583A3 (de) Imidazo[4,5-c]-pyridin-4-on-derivate
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
TW349865B (en) Therapeutic agent for hemorrhoidal diseases
AU2002213419A1 (en) Condensed pyridoindole derivatives
TWI262794B (en) Catheter composition and uses thereof
WO2002059327A3 (en) Sulfatases and methods of use thereof
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
AUPQ866500A0 (en) Therapeutic compounds and methods
WO2001097790A3 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
CY2582B2 (en) New imidazopyridines and oxazolopyridines
AU2001252772A1 (en) Use of amines

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120215